Conditional Survivorship of Osteochondral Allograft Transplantation in the Knee
Orthopaedic journal of sports medicine · 2026
Knee OCA grafts fail mostly in the first 3 years (4.9%/yr); clear that window and 10-year survival odds jump to ~90%.
Studiet
Retrospective case series, Level of evidence 4, n=288 knees (267 patients) undergoing osteochondral allograft transplantation by a single surgeon, minimum 10-year follow-up.
Hvad de fandt
Overall 10-year graft survivorship was 78%; 22% of knees (64/288) failed at a median of 2.7 years. Annual failure rate was 4.9% in the first 3 years, falling to 1.5% from years 3-10, and grafts still intact at 4 years had a 90% probability of surviving to 10 years.
Studiedesign
Single-surgeon retrospective case series, Level of evidence 4, no comparison group, n=288 knees with a long (10-year minimum) follow-up window spanning 1997 to 2015.
Metode
This is a retrospective single-surgeon case series with no control arm and no randomisation, so it cannot tell you how OCA compares to any alternative treatment, only how this graft behaves over time. Single-surgeon design limits generalisability (technique, indications, and rehab protocol are one person's practice) and there is inherent selection bias in who gets offered OCA and who is retained in a long follow-up cohort. The piecewise linear regression on inverse Kaplan-Meier curves and the conditional survivorship (CS) calculation are reasonable statistical choices for describing hazard over time, but failure was defined narrowly as reoperation with graft removal, which will undercount silent or unaddressed graft degeneration that patients tolerate without further surgery. Funding and COI are not stated in the abstract, which matters given OCA cases often involve tissue bank or device-adjacent relationships.
Vurderingen
This is a descriptive, single-surgeon, single-center case series with no control group and no adjustment for confounders like lesion size, prior surgery, or alignment, so it cannot tell you why grafts failed, only when. The large sample and genuinely long follow-up (10+ years, some to 23.6) are real strengths, and the piecewise/conditional survivorship modeling is methodologically sound for what it is, a time-to-event description. A key limitation not to gloss over: 'failure' here means reoperation with graft removal only, there is no PROMs or functional outcome data, so a graft that 'survives' on this curve could still belong to a knee with ongoing pain or limited function that just hasn't been revised. Results also come from one high-volume expert's practice and may not generalize to lower-volume centers or different patient selection.
Begrænsningen
There's no analysis of which baseline factors (age, lesion size, alignment, prior surgery) predict who falls into the high-risk early-failure group versus the low-risk survivors, so the finding describes a population average risk curve rather than something you can apply to an individual patient in front of you.
Referencestudie
This sits within an established body of OCA survivorship literature from high-volume cartilage restoration centers reporting 10-15 year outcomes; it doesn't overturn any of that, but it appears to be the first to apply conditional survivorship modeling to this procedure, showing failure risk isn't flat over time.
Hvad du gør på mandag
It doesn't change surgical indications or technique, but it gives you a concrete counseling script: tell OCA patients the first 3 to 4 years carry the real risk of reoperation or graft failure, and if they get past that window intact, their odds of a durable graft to 10 years are very good (~90%). Be precise with patients that 'durable graft' means it hasn't been surgically removed, not that it's pain-free or high-performing, this study doesn't report functional outcomes.
In practice
Applies to post-op knee OCA patients in clinic (often young, trauma or OCD-driven focal defects) and to any athlete an S&C coach inherits after this surgery. In the physio clinic, use this to justify closer, structured monitoring (effusion, mechanical symptoms, pain) through year 1-3 rather than tapering review once the wound's healed, since that's where 4.9%/yr risk and most nonfailure reoperations (median 1.5 yrs) cluster, and you can honestly reassure a patient who's clean at 4 years that the graft is very likely to go the distance. On the performance floor, this backs a genuinely graded 2-3 year return to full unrestricted cutting/pivoting load rather than clearing someone at the 9-12 month tissue-healing mark, the failure curve is a second, independent argument for conservative progression, not just cartilage maturation timelines. Caveat in application: this is a population-average risk curve with no individual risk stratification (lesion size, alignment, age not modelled here), so don't use it to reassure or restrict any one athlete without factoring in their own surgical and lesion characteristics, and remember 'survived' means not revised, not necessarily performing at prior level.
De fem studier, der betyder noget — hver uge, gratis.
Vi læser hele litteraturen om sportsmedicin, genoptræning og præstation og vurderer de studier, der er din tid værd.
Få den gratis ugentlige udgaveRelaterede vurderinger
Læs på dit sprog: English · Français · Deutsch · Español · Italiano · Nederlands · Dansk · Svenska